Kirsten A Grüneberg

Partner at Grüneberg and Myers PLLC
Ranked in IP management consultancy, Legal, M&A
IAM Research

The IAM Strategy 300 focuses exclusively on patent practitioners and has firmly established itself as the definitive 'go-to' resource for those seeking world-class legal patent expertise.

IAM Says

Kirsten Grüneberg is “incredibly business savvy and a go-getter who you want to have on your side”. She consistently produces top-quality patent work and is extremely responsive: “She takes things on at short notice, is ready to discuss cases over the phone and makes time to get back to spontaneous enquiries.”

Kirsten A Grüneberg's Profile

Kirsten A Grüneberg established the Grüneberg and Myers firm in 2017, aiming to provide a high-quality service while maximising efficiency and minimising internal bureaucracy and expense. With a business model differing from many traditional law firms, Grüneberg and Myers is highly adaptable to the economic requirements of corporate clients. Dr Grüneberg leads a team of professionals with extensive experience in intellectual property, ranging from chemical, pharmaceutical and biotech to electrical and mechanical technologies, bolstering their ability to deliver on these goals. Within three years, the firm was recognised as one of the world’s leading IP firms. Dr Grüneberg has the rare honour of being listed in IAM Patent 1000 as well as IAM Strategy 300, which name the world’s top IP professionals and IP strategists.

Dr Grüneberg supports many of the world’s largest chemical, biotech and pharmaceutical companies, including Fortune 50, Fortune Global 200, DAX 30 and Nikkei 225 companies, in addressing their IP and business needs. She counsels clients on freedom-to-operate opinions, prosecution, worldwide portfolio management and post-grant proceedings, including inter partes reviews and re-examination. Dr Grüneberg also has significant experience with IP issues in mergers and acquisitions in the United States, Europe and Asia. Dr Grüneberg has successfully defended high-value pharmaceutical patents in post-grant proceedings, helping to secure business deals worth several hundred million dollars. She is also active on the post-grant petitioner side.

After receiving her PhD in organic chemistry, magna cum laude, from the Technical University of Berlin, Dr Grüneberg was awarded a Lynen Fellowship from the Alexander von Humboldt Foundation in Germany to perform research at the Centre for Bio/Molecular Science and Engineering at the US Naval Research Laboratory. She was a visiting professor at Georgetown University Medical Centre in Washington DC. She also worked as a senior scientist at Geo-Centres Inc and the US Naval Research Laboratory, and as a research scientist at the Max Planck Institute of Colloids and Interfaces in Berlin.

Unlock unlimited access to all IAM content